Amoéba's Stock Rises by 3.42% Following Dutch Approval for AXPERA

A Regulatory Momentum Building Around AXPERA

Today's rebound follows a Dutch authorization obtained with Koppert for large-scale trials of AXPERA in the Netherlands. These exemptions, valid for two years, allow the marketing of crops resulting from these trials. It is worth noting that the company also secured an emergency market authorization in France against vine mildew in late April, valid for 120 days. These successive approvals come during the commercial launch phase of the biofungicide, following a fundraising of €6.67 million completed at the end of March 2026, which also helped push back the group's debt balance to 2029. The fiscal year 2025 ended with a net loss of €8.3 million, with increased industrial investments to prepare for the ramp-up of AXPERA.

Stock Price Faces Resistance at €0.89

The stock is priced at €0.91, slightly surpassing its identified resistance at €0.89, which also corresponds to the upper limit of the Bollinger Bands. The RSI at 50 remains neutral, showing no signs of excess. The 50-day moving average, at €0.92, is just above the current price, and the 200-day moving average at €0.95 remains out of reach in the short term. The negative beta of -0.25 illustrates the stock's decoupling from the Paris market, as evidenced in today's session with Amoéba's rise while the SBF 120 falls by 0.86%. Over seven days, the stock has gained 4.37%, emerging from a nearly stagnant zone observed over three months (-0.98%). The ability of the price to stay above €0.89 will be the first numerical reference for the ongoing momentum.